• Radiation Therapy
      • Treatment Delivery
        • Elekta Unity Elekta Unity
        • Elekta Versa HD Elekta Versa HD
        • Elekta Harmony Elekta Harmony
        • Elekta Infinity Elekta Infinity
      • Quality Assurance
        • Machine QA
        • Patient QA
    • Stereotactic Radiosurgery
      • Delivery
        • Elekta Esprit Elekta Esprit
        • Versa HD Versa HD
      • Treatment Planning
        • Leksell GammaPlan
    • Oncology Software
      • Elekta ONE
        • Oncology care
        • Smart Workflows
        • Treatment Applications
        • Real-world outcomes
        • Subscribe to Better
        • Elekta Axis Cloud
        • Interoperability
        • Professional Services
    • Brachytherapy
      • Delivery
        • Elekta Studio Elekta Studio
        • ImagingRing ImagingRing
        • Oncentra Brachy Oncentra Brachy
        • Venezia Venezia
        • Flexitron Flexitron
        • Geneva Geneva
        • Xoft Xoft
      • Body Sites
        • Head and Neck
        • Bronchus and Oesophagus
        • Breast
        • Skin
        • Prostate
        • Brachytherapy for rectal cancer
        • Bladder
        • Cervix
    • Neurosurgery
      • Delivery
        • Leksell Vantage Stereotactic System Leksell Vantage Stereotactic System
    • Veterinary Radiation Therapy
    • Life Sciences
      • Elekta Kaiku
    • Elekta Care
    • Elekta Care Support Services
    • Elekta Care 360
    • Elekta Care Learning
    • Elekta Care Community
    • Elekta Partner Community
    • MR-Linac Treatment
    • Brachytherapy Treatment
    • Gamma Knife Treatment
    • Radiation Therapy Treatment
    • Treatment Centers
    • Company
    • Partnering with Elekta
    • About us
      • About us
        • Board of Directors
        • Code of Conduct
        • Corporate Citizenship
        • Executive Committee
        • Integrity Line
        • Programs
        • Risk management
        • Sponsorship and Donation
        • Story
    • Sustainability
    • Corporate Governance
      • Corporate Governance
        • Shareholders’ meetings
          • Board of Directors
            • Executive Committee
              • Auditors
              • Reports
          • Investors
            • Investors
              • Investment case
                • Outlook
                • Market and Trends
                  • The share
                    • Financials
                      • Funding
                        • Reports & presentations
                        • Press releases
                        • IR calendar
                        • IR contacts
                    • Newsroom
                      • Newsroom
                        • Press Releases
                        • FOCUS Magazine
                        • Events
                        • Image bank
                    • Careers at Elekta
                      • Jobs
                    • Reimbursement Support & Policy
                  ENSV
                  Login
                  • Products
                    • Radiation Therapy
                      • Treatment Delivery
                        • Elekta Unity
                        • Elekta Versa HD
                        • Elekta Harmony
                        • Elekta Infinity
                      • Quality Assurance
                        • Machine QA
                        • Patient QA
                    • Stereotactic Radiosurgery
                      • Delivery
                        • Elekta Esprit
                      • Treatment Planning
                        • Leksell GammaPlan
                      • Versa HD
                    • Oncology Software
                      • Elekta ONE
                        • Oncology care
                        • Smart Workflows
                        • Treatment Applications
                        • Real-world outcomes
                        • Subscribe to Better
                        • Elekta Axis Cloud
                        • Interoperability
                        • Professional Services
                    • Brachytherapy
                      • Elekta Studio
                      • ImagingRing
                      • Venezia
                      • Flexitron
                      • Geneva
                      • Head and Neck
                      • Bronchus and Oesophagus
                      • Xoft
                      • Breast
                      • Skin
                      • Prostate
                      • Brachytherapy for rectal cancer
                      • Bladder
                      • Cervix
                      • Oncentra Brachy
                    • Neurosurgery
                      • Leksell Vantage Stereotactic System
                    • Veterinary Radiation Therapy
                    • Life Sciences
                      • Elekta Kaiku
                  • Services
                    • Elekta Care
                    • Elekta Care Support Services
                    • Elekta Care 360
                    • Elekta Care Learning
                    • Elekta Care Community
                    • Elekta Partner Community
                  • Patients
                    • MR-Linac Treatment
                    • Brachytherapy Treatment
                    • Gamma Knife Treatment
                    • Radiation Therapy Treatment
                    • Treatment Centers
                  • Company
                    • Partnering with Elekta
                    • About us
                      • Board of Directors
                      • Code of Conduct
                      • Corporate Citizenship
                      • Executive Committee
                      • Integrity Line
                      • Programs
                      • Risk management
                      • Sponsorship and Donation
                      • Story
                    • Sustainability
                    • Corporate Governance
                      • Shareholders’ meetings
                        • Board of Directors
                          • Executive Committee
                            • Auditors
                            • Reports
                          • Investors
                            • Investment case
                              • Outlook
                              • Market and Trends
                                • The share
                                  • Financials
                                    • Funding
                                      • Reports & presentations
                                      • Press releases
                                      • IR calendar
                                      • IR contacts
                                    • Newsroom
                                      • Press Releases
                                      • FOCUS Magazine
                                      • Events
                                      • Image bank
                                    • Careers at Elekta
                                      • Jobs
                                    • Reimbursement Support & Policy
                                  • Contact
                                  • Medical Affairs
                                  • Regulatory Affairs
                                  • Suppliers
                                    • About Elekta Procurement
                                    • Sustainable Sourcing
                                    • Performance Management
                                      • Production Part Approval Process
                                      • Supplier Escalation Form
                                      • Non Conformance Management
                                      • Supplier Performance Management
                                      • Obsolescence Management
                                    • Compliance Management
                                    • Invoicing Process
                                    • Elekta T&C
                                    • Documents & Training
                                    • Our Global Presence

                                  Elekta - Interim report May – October 2015/16

                                  December 04, 2015

                                  Second quarter
                                  -      Order bookings increased 14 percent to SEK 3,291 M (2,876) or 3 percent based on constant exchange rates.
                                  -      Net sales increased 10 percent to SEK 2,828 M (2,567) or decreased 1 percent based on constant exchange rates.
                                  -      EBITA amounted to SEK 444 M (397) before non-recurring items of SEK -18 M (0). Operating result was SEK 304 M (310).
                                  -      Net income amounted to SEK 189 M (200). Earnings per share was SEK 0.49 (0.52) before dilution and SEK 0.49 (0.52) after dilution.
                                  -      Cash flow after continuous investments amounted to SEK 147 M (173).

                                  May – October
                                  -      Order bookings increased 12 percent to SEK 5,827 M (5,217) or decreased 1 percent based on constant exchange rates.
                                  -      Net sales increased 14 percent to SEK 5,067 M (4,432) or 1 percent based on constant exchange rates.
                                  -      EBITA amounted to SEK 485 M (359) before non-recurring items of SEK -48 M (-2). Operating result was SEK 211 M (188).
                                  -      Net income amounted to SEK 60 M (63). Earnings per share was SEK 0.15 (0.16) before dilution and SEK 0.15 (0.16) after dilution.
                                  -      Cash flow after continuous investments amounted to SEK -417 M (-497).

                                  Outlook
                                  We expect growth in net sales to continue to be modest for the fiscal year, based on constant exchange rates, and that the EBITA margin, adjusted for non-recurring items, will continue to improve.

                                  The outlook is adjusted from the previous: “We expect negative growth in net sales for the first half of 2015/16, while growth is expected to return during the second half of 2015/16.”

                                  President and CEO comments
                                  During the first half of our fiscal year, net sales grew 14 percent or 1 percent based on constant exchange rates. Gross margin increased 2.3 percentage points and EBITA improved by SEK 126* M. The improvements are mainly driven by growth in service and aftermarket sales and partly due to that deliveries scheduled for the third quarter now were completed already in the first half year. Order bookings in the second quarter increased 14 percent or 3 percent based on constant exchange rates. Growth was particularly strong in region Europe, Middle East and Africa.

                                  Transformation program on track
                                  The transformation program is proceeding according to plan, including the target to reach an EBITA margin improvement of more than 6 percentage points by the end of fiscal year 2017/18**. The cost reduction of SEK 450 M is on track with savings primarily in administration, supply chain and procurement. At the end of the quarter our workforce has been reduced with 91 employees.

                                  Strong product offering and innovation portfolio
                                  We continue to prioritize strategic R&D investments to improve cancer care, for example our software solutions and image guided radiation therapy. We are also improving our customer service network including training and education.

                                  During the quarter, the new Leksell Gamma Knife Icon system received FDA clearance in the US. Our MRI-guided radiation therapy program, Atlantic, is progressing according to plan. The R&D consortium’s second non-commercial system was recently installed at MD Anderson Cancer Center in Houston, US. Installations at the five remaining consortium sites will take place during the 2016 calendar year.

                                  Reducing net working capital
                                  Cash flow after continuous investments improved by SEK 80 M for the first half year to SEK -417 M. Net working capital in relation to last 12 months net sales decreased to 11 percent (16), a level that we are not satisfied with. Programs for improvement have been initiated and will lower net working capital. The target is a reduction with over SEK 200 M by the end of 2016/17.

                                  Zero tolerance
                                  As previously communicated, there is an ongoing investigation in Italy where Elekta employees are suspected of interfering with public procurement processes. Elekta is providing all requested information to the Italian authorities. We have zero tolerance for any deviation from our code of conduct and clear corporate policies and procedures in place.

                                  Tomas Puusepp
                                  President and CEO

                                  * Before non-recurring items
                                  ** Base year 2014/15, excluding currency effects

                                    
                                  Shareholder information

                                  Conference call
                                  Elekta will host a telephone conference at 10:00-11:00 CET on December 4, with President and CEO Tomas Puusepp and CFO Håkan Bergström.

                                  To take part in the conference call, please dial in about five minutes in advance.

                                  Swedish dial-in number: +46 (0)8 566 426 64
                                  UK dial-in number: +44 (0) 203 428 14 09
                                  US dial-in number: + 1 855 753 22 36

                                  The telephone conference will also be broadcasted over the internet (listen only). Please use the link:

                                  http://event.onlineseminarsolutions.com/r.htm?e=1096935&s=1&k=195FCFCFA7C622F68F04F81204962886

                                  For further information, please contact:

                                  Håkan Bergström
                                  CFO, Elekta AB (publ)
                                  +46 8 587 25 547,
                                  [email protected]

                                  Johan Andersson
                                  Director Investor Relations, Elekta AB (publ)
                                  +46 8 587 25 415
                                  [email protected]

                                  Downloads

                                  • Interim report May – October 2015/16 (PDF)
                                  • Products
                                    • Radiation Therapy
                                    • Stereotactic Radiosurgery
                                    • Oncology Software
                                    • Brachytherapy
                                    • Neurosurgery
                                    • Veterinary Radiation Therapy
                                    • Life Sciences
                                  • Services
                                    • Elekta Care
                                    • Elekta Care Support Services
                                    • Elekta Care 360
                                    • Elekta Care Learning
                                    • Elekta Care Community
                                    • Elekta Partner Community
                                  • Patients
                                    • MR-Linac Treatment
                                    • Brachytherapy Treatment
                                    • Gamma Knife Treatment
                                    • Radiation Therapy Treatment
                                    • Treatment Centers
                                  • Company
                                    • Partnering with Elekta
                                    • About us
                                    • Sustainability
                                    • Corporate Governance
                                    • Investors
                                    • Newsroom
                                    • Careers at Elekta
                                    • Digital Product Security
                                    • Offices
                                    • Regional pages
                                  • ©2025 Elekta
                                  • Legal notices
                                  • Privacy policy
                                  • Cookies
                                  • Subscription center

                                  Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.

                                  © 2025 Elekta

                                  • Legal notices
                                  • Privacy policy
                                  • Cookies
                                  • Subscription center

                                  Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.